Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34(−) and immature CD34(+) cells

Accumulation in target cells is an essential pharmacokinetic step of targeted therapies. Tyrosine Kinase Inhibitors (TKI) against the BCR-ABL fusion protein in Chronic Phase-Chronic Myeloid Leukaemia (CP-CML) cells constitute a unique model in terms of efficacy, specificity, and in vivo demonstratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Berger, Marc G., Lebecque, Benjamin, Tassin, Thomas, Dannus, Louis-Thomas, Berger, Juliette, Soucal, Mélanie, Guerci, Agnès, Cony-Makhoul, Pascale, Johnson, Hyacinthe, Etienne, Gabriel, Guyotat, Denis, Gagnieu, Marie-Claude, Pereira, Bruno, Saugues, Sandrine, Tournilhac, Olivier, Hermet, Eric, Bourgne, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969931/
https://www.ncbi.nlm.nih.gov/pubmed/33731863
http://dx.doi.org/10.1038/s41598-021-85734-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969931/
https://www.ncbi.nlm.nih.gov/pubmed/33731863
http://dx.doi.org/10.1038/s41598-021-85734-0

Ejemplares similares